The Effect of Mild Cognitive Impairment Management Program on Traditional Korean Medicine in a Public Health Center

Kyeong Han Kim; Su-In Lee; Kim, Kyeong Han; Lee, Su-In

doi:10.13048/jkm.13016

JKM > Volume 34(3); 2013 > Article

Kim and Lee: The Effect of Mild Cognitive Impairment Management Program on Traditional Korean Medicine in a Public Health Center

Original Article

Journal of Korean Medicine 2013; 34(3): 106-118.

Published online: September 30, 2013

DOI: https://doi.org/10.13048/jkm.13016

The Effect of Mild Cognitive Impairment Management Program on Traditional Korean Medicine in a Public Health Center

Kyeong Han Kim, Su-In Lee

Department of Traditional Korean Medicine of Uijeongbu-city Public Health Center

Correspondence to: 김경한(Kyeong Han Kim), 경기도 의정부시 의정부시보건소, Tel : +82-31-850-5883, Fax : +82-31-873-7719, E-mail : solip922@hanmail.net

Received July 04, 2013 Revised September 02, 2013 Accepted September 11, 2013

Abstract

Objectives:

The aim of this study was to evaluate the effect of a mild cognitive impairment (MCI) management program on traditional Korean medicine in a public health center.

Methods:

In order to examine the effect of the MCI management program, we investigated MCI patients who participated in the program. MCI patients were treated with Jodeung-san (JDS) or Dangguijagyag-san (DGJYS) for 6 weeks. Mini Mental State Examination-Dementia Screening (MMSE-DS), Geriatric Quality of Life-Dementia (GQOL-D), Geriatric Depression Scale in Korea (GDS-K), and biochemical examination of blood were conducted at intervals of 6 weeks. A satisfaction survey was collected after this program.

Results:

MMSE-DS mean score increased significantly, by 4.09 (p=0.000) in the JDS group and by 4.15 (p=0.000) in the DGJYS group. GQOL-D mean score also increased significantly, by 5.90 (p=0.000) in the JDS group and by 5.07 (p=0.000) in the DGJYS group. GDS-K mean score decreased significantly, by 10.63 (p=0.000) in the JDS group and by 9.69 (p=0.000) in the DGJYS group. MMSE-DS, GDS-K and GQOL-D scores were not significantly different between the JDS and DGJYS groups. All of the participants were satisfied with the program, and 90% of the participants expressed a high intention to participate in the program again.

Conclusions:

Both Jodeung-san and Dangguijagyag-san treatment showed improvement on cognitive function, depression and quality of life in this program. Additional studies with more subjects will be required to prove credibility and validity more clearly.

Keywords: Jodeung-san, Dangguijagyag-san, MCI, MMSE-DS, GDS-K, GQOL-D

Fig. 1.

Change of MMSE-DS Scores with the Program

Fig. 2.

Change of GDS-K Scores with the Program

Fig. 3.

Change of GQOL-D Scores with the Program

Fig. 4.

Satisfaction after the Program

Fig. 5.

Changes in perception of MCI after the Program

Fig. 6.

Re-participation Intention after the Program

Table 1.

Composition of JDS

Composition	Amount	Unit
JDS extract contain dried extract of the following mixed crude drugs	1.5	g
Gypsum	1.7	g
Uncaria Hook	1.0	g
Citrus Unshiu Peel	1.0	g
Ophiopogon Tuber	1.0	g
Pinellia Tuber	1.0	g
Poria Sclerotium	1.0	g
Chrysanthemum Flower	0.7	g
Ginseng	0.7	g
Saposhnikovia Root	0.7	g
Glycyrrhiza	0.3	g
Ginger	0.3	g
Lactose Hydrate	0.9875	g
Magnesium Stearate	0.0125	g

Total	2.5	g

Table 2.

Composition of DGJYS

Composition	Amount	Unit
DGJYS extract contain dried extract of the following mixed crude drugs	1.0	g
Peony Root	1.0	g
Atractylodes Lancea Rhizome	1.0	g
Alisma Rhizome	1.0	g
Poria Sclerotium	1.0	g
Cnidium Rhizome	0.75	g
Japanese Angelica Root	0.75	g
Lactose Hydrate	0.86562	g
Magnesium Stearate	0.00938	g

Total	1.875	g

Table 3.

Charateristics of Subjects

Variables		JDS Group		DGJYS Group		Total

		N	%	N	%	N	%
Sex	Male	3	27.3	2	15.4	5	20.8
	Female	8	72.7	11	84.6	19	79.2
	Total	11	100	13	100	24	100

Age		73.91±2.98		73.92±3.77		73.92±3.17
Education level		4.55±4.01		2.85±3.98		3.63±3.94
MMSE-DS		20.55±2.62		19.23±2.83		19.83±2.76
GDS-K		22.27±3.95		21.23±5.57		21.71±4.82
GQOL-D		21.55±3.11		20.85±3.74		21.17±3.41

Table 4.

Change of MMSE-DS Scores with the Program

MMSE-DS		Mean			Std. Deviation			t			Sig.(2-tailed)

		JDS	DGJYS	Total	JDS	DGJ YS	Total	JDS	DGJYS	Total	JDS	DGJYS	Total
Orientation	Before	8.45	7.69	8.04	1.44	1.70	1.61	−2.14	−2.41	−3.29	0.058	0.033^*	0.003^**
Orientation	After	9.45	8.85	9.12	0.69	1.07	0.95	−2.14	−2.41	−3.29	0.058	0.033^*	0.003^**
Attention	Before	1.64	1.08	1.33	1.43	1.32	1.37	−2.89	−3.09	−4.29	0.016^*	0.009^**	0.000^**
Attention	After	2.55	2.15	2.33	1.04	1.86	1.52	−2.89	−3.09	−4.29	0.016^*	0.009^**	0.000^**
Memory	Before	4.18	4.15	4.17	0.98	0.90	0.92	−1.17	−2.21	−2.4	0.267	0.047^*	0.024^*
Memory	After	4.55	4.69	4.63	1.04	0.95	0.97	−1.17	−2.21	−2.4	0.267	0.047^*	0.024^*
Language	Before	4.00	4.46	4.25	0.77	0.78	0.79	−7.06	−3.86	−7.0	0.000^**	0.002^**	0.000^**
Language	After	5.45	5.38	5.42	0.69	0.65	0.65	−7.06	−3.86	−7.0	0.000^**	0.002^**	0.000^**
Visuospatial ability	Before	0.45	0.15	0.29	0.52	0.38	0.46	−1.49	−1.48	−2.15	0.167	0.165	0.043^*
Visuospatial ability	After	0.64	0.31	0.46	0.50	0.48	0.51	−1.49	−1.48	−2.15	0.167	0.165	0.043^*
Judgement	Before	1.82	1.77	1.79	0.40	0.44	0.41	−1.49	−1.90	−2.46	0.167	0.082	0.022^*
Judgement	After	2.00	2.00	2.00	0.00	0.00	0.00	−1.49	−1.90	−2.46	0.167	0.082	0.022^*
Total	Before	20.55	19.23	19.83	2.62	2.83	2.76	−5.59	−7.22	−9.21	0.000^**	0.000^**	0.000^**
Total	After	24.64	23.38	23.96	1.75	1.80	1.85	−5.59	−7.22	−9.21	0.000^**	0.000^**	0.000^**

* p<0.05,

** p<0.01

Table 5.

Change of GDS-K Scores with the Program

		GDS-K
		Mean	Std. Deviation	t	Sig.(2-tailed)
JDS Group	Before	22.27	3.95	9.92	0.000^**
JDS Group	After	11.64	4.57	9.92	0.000^**
DGJYS Group	Before	21.23	5.57	8.00	0.000^**
DGJYS Group	After	11.54	4.94	8.00	0.000^**
Total	Before	21.71	4.82	12.53	0.000^**
Total	After	11.58	4.67	12.53	0.000^**

* p<0.05,

** p<0.01

Table 6.

Change of GQOL-D Scores with the Program

		GQOL-D
		Mean	Std. Deviation	t	Sig.(2-tailed)
JDS Group	Before	21.55	3.11	−7.26	0.000^**
JDS Group	After	27.45	3.88	−7.26	0.000^**
DGJYS Group	Before	20.85	3.74	−5.06	0.000^**
DGJYS Group	After	25.92	4.01	−5.06	0.000^**
Total	Before	21.17	3.41	−8.38	0.000^**
Total	After	26.63	3.94	−8.38	0.000^**

* p<0.05,

** p<0.01

Table 7.

Difference of Scores between JDS and DGJYS Group

		Mean Difference	Std. Deviation	F	Sig.(2-tailed)
MMSE-DS	JDS Group	4.09	2.43	0.097	0.758
MMSE-DS	DGJYS Group	4.15	2.08	0.097	0.758
GQOL-D	JDS Group	5.91	2.70	0.028	0.868
GQOL-D	DGJYS Group	5.08	3.62	0.028	0.868
GDS-K	JDS Group	−10.64	3.56	0.215	0.648
GDS-K	DGJYS Group	−9.69	4.37	0.215	0.648

* p<0.05,

** p<0.01

Table 8.

Change of biochemical examination of blood with the Program

		JDS Group		DGJYS Group

		M±SD	Sig.(2-tailed)	M±SD	Sig.(2-tailed)
AST	Before	27.09±10.92	0.592	25.31±7.81	0.335
AST	After	25.73±18.82		23.15±3.76
ALT	Before	18.82±9.52	0.471	19.31±7.34	0.829
ALT	After	19.82±6.43		18.85±5.51
rGPT	Before	42.82±43.62	0.913	36.31±46.00	0.114
rGPT	After	41.45±60.26		33.54±44.58
BUN	Before	16.06±3.29	0.260	14.55±3.74	0.472
BUN	After	18.11±6.20		15.54±3.05
Creatinine	Before	0.94±0.25	0.736	0.84±0.12	0.223
Creatinine	After	0.92±0.30		0.78±0.18
Uric acid	Before	5.63±1.45	0.346	5.13±1.18	0.069
Uric acid	After	5.30±0.82		4.84±1.01

* p<0.05,

** p<0.01

References

1.. Statistics Korea. Future Population Projection. Statistics Korea;2012.

2.. Ministry of Health & Welefare. Survey of Dementia Prevalence Rate. Ministry of Health & Welefare;2008.

3.. Ku BD, Kim SG, Lee JY, Park KH, Shin JH, Kim KK, et al. Clinical practice guideline for dementia by Clinical Research Center for Dementia of South Korea. J Korean Med Assoc. 2011; 54:8. 861–875.

4.. Choi KG. Neuropathology of MCI-View from Relationships with Aging and Alzheimer’s Disease-. Dementia and Neurocognitive Disorders. 2003; 2:101–107.

5.. Petersen RC, Doody R, Kurz , Mohs RC, Morris JC, Rabins PV, et al. Current Concepts in Mild Cognitive Impairment. Arch Neurol. 2001; 58:1985–1992.

6.. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Aging, memory, and mild cognitive impairment. Int Psychogeriatr. 1997; 9:1. 65–69.

7.. Shah Y, Tangalos EG, Petersen RC. Mild cognitive impairment. When is it a precursor to Alzheimer’s disease? Geriatrics. 2000; 55:65–68.

8.. Flicker C, Ferris SH, Reisberg B. Mild cognitive impairment in the eldery: predictiors of dementia. Neurology. 1991; 41:1006–1009.

9.. Ministry of Health & Welefare. National Epidemiologic Investigation. Ministry of Health & Welefare;2008.

10.. Han CS, Lee JY, Lee DW, Ryu SH, Lee KJ, Kim JH, et al. Development of Hybrid Model for Integrating Management of Geriatric Depression and Dementia in Urban Area. J Korean Geriatr So. 2006; 10:2. 104–114.

11.. John KA, Heather BB. The sensitivity of the Beck Depression Inventory to changes of symptomatology. Br J Psychiatry. 1974; 125:184–185.

12.. Peter R. Ageing and the brain. Postgrad Med J. 2007; 82:84–88.

13.. Heo EJ, Kang JS, Kang HW, Jeon WK. Evaluation on the Quality of Research Field with Traditional Herbal Prescriptions for Dementia Therapy. J of Oriental Neuropsychiatry. 2012; 23:1. 93–114.

14.. Murakami Y, Zhao Q, Harada K, Tohda M, Watanabe H, Matsumoto K. Choto-san, a Kampo formula, improves chronic cerebral hypo-perfusion-induced spatial learning deficit via stimulation of myscarinic M1 receptor. Pharmacology Biochemistry and Behavior. 2005; 81:3. 616–625.

15.. Koichi Y, Yutaka S, Etsuro H, Nobuyasu S, Hirozo G, Owao S, et al. Protective effects of Choto-san and hooks and stems of Uncaria sinesis against delayed neuronal death after transient forebrain ischemia in gerbil. Phytomedicine. 2004; 11:478–489.

16.. Watanabe H, Zhao Q, Matsumoto K, Tohda M, Murakami Y, Zhang SH, et al. Pharmacological evidence for antidementia effect of Chotosan(Guteng-san), a traditional Kampo medicine. Pharamacol Biochem Behav. 2003; 75:3. 635–643.

17.. Mizushima Y, Kan S, Yoshida S, Irie Y, Urata Y. Effect of Choto-san a Kampo medicine, on impairment of passive avoidance performance in senescence accelerated mouse(SAM). Phytotherapy research. 2003; 17:542–545.

18.. Matsuoka T, Narumoto J, Shibata K, Okamura A, Taniguchi S, Kitabayashi Y, et al. Effect of Toki-Shakuyaku-San on Regional Cerebral Blood Flow in Patients with Mild Cognitive Impairment and Alzheimer’’s Disease. Evi-Based Com and Alt Med. 2012.

19.. Inanaga K, Dainoson K, Ninomiya Y, TAkii O, Omaru M, Tanaka T, et al. Effects of Toko-Shakuyaku-San in Patients with Senile Cognitive Disoreders. Progress in Medicine. 1996; 16:293–300. 1996.

20.. Iwasaki K, Satoh-Nakaqawa T, Maruyama M, Monma Y, Tomita N, Tanji H, et al. A randomized, observer-blind, controlled trial of the traditional Chinese medicine Yi-Gan San for improvement of behavioral and psychological symtoms and activities of daily living in dementia patients. J Clin Psychiatry. 2005; 66:2. 248–252.

21.. Folstein MF, Folstein SE. “Mini-Mental State”: a practical method for grading the cognitive state of patients for the clinician. J of Psych Res. 1975; 12:189–198.

22.. Park JH, Kwon YC. Standardization of Korean of the Mini-Mental State Examination (MMSE-K) for Use in the Elderly-Part II. Diagnostic Validity. J Korean NeuroPsychiatric Assoc. 1989; 28:508–513.

23.. Kang YW, Na DY, Han SH. A Validity Study on the Korean Mini-Mental State Examination (K-MMSE) in Dementia Patients. J Korean Neurol Assoc. 1997; 15:300–307.

24.. Lee JH, Lee KU, Lee DY, Kim KW, Kim JH, Lee KH, et al. Development of the Korean version of the consortium to establish a registry for alzheimer’s disease assessment packet (CERAD-K): clinical and neuro-psychological assessment batteries. J Gerontology Series B: Psychological Sciences and Social Sciences. 2002; 57:1. 47–53.

25.. Han JW, Kim TH, Joo JH, Park JH, Kim JR, Yoo SH, et al. A Normative Study of the Mini-Mental State Examination for Dementia Screening (MMSE-DS) and Its Short form (SMMSE-DS) in the Korean Elderly. J Korean Geriatr Psychiatry. 2010; 14:1. 27–37.

26.. Lee HS, Kim JH, Ko HJ, Ku HM, Kwon EJ, Shin JY, et al. The Standardization of the Geriatric Quality of Life scale-Dementia(GQOL-D). J Korean Geriatr Soc. 2004; 8:3. 151–164.

27.. Ki BS, Lee CW. A Preliminary Study for the Standardization of Geriatric Depression Scale in Korea. J Korean NeuroPsychiatric Assoc. 1995; 129:1875–1885.

28.. Ministry of Health & Welefare. Direction for Korean Medicine Health Promotion Program in 2013. Ministry of Health & Welefare;2012.

29.. Gyeonggi Statistical Information Service. Population Statistics. Gyeonggi Statistical Information Service;2012.

30.. Choi SH, Na DL, Oh KM, Park BJ. A Short form of the Samsung Dementia Questionnaire (S-SDQ): development and cross-validation. J Korean Neurol Assoc. 1997; 17:2. 253–258.

31.. Galasko D, Kauber MR, Hoftetter R, Salmon DP, Lasker B, Thal LJ. The mini-mental state examination in the elderly diagnosis of Alzheimer’ disease. Arch Neurol. 1990; 47:1. 49–52.

32.. Clark CM, Sheppard L, Fillenbaum GG, Galasko D, Morris JC, Koss E, et al. Variability in annual Mini-Mental State Examination score in patients with probable Alzheimer disease: a clinical perspective of data from the Consortium to Establish a Registry for Alzheimer’s Disease. Arch Neurol. 1999; 56:7. 857–862.

33.. Lee KS, Jung HK, Oh BH, Hong CH. Comparison of the Validity of Screening Tests for Dementia and Mild Cognitive Impairment of the Elderly in a Community K-MMSE, MMSE-K, MMSE-KC, and K-HDS. J Korean NeuroPsychiatric Assoc. 2009; 48:2. 61–69.

34.. Nasreddine ZS, Phillips NA, Béirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J American Geriatrics Society. 2005; 53:4. 695–699.